OPT302

Published

dm+d

Unassigned

New Medicines

Information

New molecular entity
Opthea
Opthea

Development and Regulatory status

Phase III Clinical Trials
Phase III Clinical Trials
Phase III Clinical Trials

Category

OPT-302 is a soluble form of vascular endothelial growth factor receptor 3 (VEGFR-3) or ‘Trap’ molecule that blocks the activity of two proteins (VEGF-C and VEGF-D). Effects are additive to VEGF-A inhibitos such as ranibizumab.
Wet AMD is the leading cause of blindness in the developed world in individuals aged over 50 years, the estimated prevalence of AMD in the UK is 4.8% of those over 65 years of age and 12.2% of those aged 80 years or more [2].
Wet age-related macular degeneration
Intravitreal